A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

Kakiuchi-Kiyota, Satoko; Ross, Thorsten; Wallweber, Heidi Ackerly; Kiefer, James R.; Schutten, Melissa M.; Adedeji, Adeyemi O.; Cai, Hao; Hendricks, Robert; Cohen, Sivan; Myneni, Srividya; Liu, Luna; Fullerton, Aaron; Corr, Nicholas; Yu, Lanlan; de Almeida Nagata, Denise; Zhong, Shelly; Leong, Steven R.; Li, Ji; Nakamura, Rin; Sumiyoshi, Teiko; Li, Jinze; Ovacik, Ayse Meric; Zheng, Bing; Dillon, Mike; Spiess, Christoph; Wingert, Susanne; Rajkovic, Erich; Ellwanger, Kristina; Reusch, Uwe; Polson, Andrew G.

doi:10.1038/s41375-021-01478-w

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

Journal Article · 10 January 2022 · Leukemia

DOI:https://doi.org/10.1038/s41375-021-01478-w· OSTI ID:1982096

Kakiuchi-Kiyota, Satoko; Ross, Thorsten; Wallweber, Heidi Ackerly; Kiefer, James R.; Schutten, Melissa M.; ; ; Hendricks, Robert; Cohen, Sivan; Myneni, Srividya; Liu, Luna; Fullerton, Aaron; Corr, Nicholas; Yu, Lanlan; de Almeida Nagata, Denise; Zhong, Shelly; Leong, Steven R.; Li, Ji; Nakamura, Rin; Sumiyoshi, Teiko more »

Not provided.

Research Organization:: SLAC National Accelerator Laboratory (SLAC), Menlo Park, CA (United States). Stanford Synchrotron Radiation Lightsource (SSRL)

Sponsoring Organization:: USDOE

DOE Contract Number:: AC02-76SF00515

OSTI ID:: 1982096

Journal Information:: Leukemia, Vol. 36, Issue 4; ISSN 0887-6924

Publisher:: Nature Publishing Group (NPG)

Country of Publication:: United States

Language:: English

References (36)

Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma Laubach, Jp; Paba Prada, Ce; Richardson, Pg Clinical Pharmacology & Therapeutics, Vol. 101, Issue 1 https://doi.org/10.1002/cpt.550	journal	December 2016
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma Richardson, Paul G.; Sonneveld, Pieter; Schuster, Michael W. New England Journal of Medicine, Vol. 352, Issue 24 https://doi.org/10.1056/NEJMoa043445	journal	June 2005
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma San Miguel, Jesús F.; Schlag, Rudolf; Khuageva, Nuriet K. New England Journal of Medicine, Vol. 359, Issue 9 https://doi.org/10.1056/NEJMoa0801479	journal	August 2008
B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma Tai, Yu-Tzu; Anderson, Kenneth C. Expert Opinion on Biological Therapy, Vol. 19, Issue 11 https://doi.org/10.1080/14712598.2019.1641196	journal	July 2019
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy Cho, Shih-Feng; Anderson, Kenneth C.; Tai, Yu-Tzu Frontiers in Immunology, Vol. 9 https://doi.org/10.3389/fimmu.2018.01821	journal	August 2018
A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells DiLillo, David J.; Olson, Kara; Mohrs, Katja Blood Advances, Vol. 5, Issue 5 https://doi.org/10.1182/bloodadvances.2020002736	journal	March 2021
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma Topp, Max S.; Duell, Johannes; Zugmaier, Gerhard Journal of Clinical Oncology, Vol. 38, Issue 8 https://doi.org/10.1200/JCO.19.02657	journal	March 2020
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf Barilà, Gregorio; Rizzi, Rita; Zambello, Renato Pharmaceuticals, Vol. 14, Issue 1 https://doi.org/10.3390/ph14010040	journal	January 2021
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies Zhou, Xiang; Rasche, Leo; Kortüm, K. Martin Frontiers in Immunology, Vol. 11 https://doi.org/10.3389/fimmu.2020.620312	journal	December 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma Bartlett, Nancy L.; Herrera, Alex F.; Domingo-Domenech, Eva Blood, Vol. 136, Issue 21 https://doi.org/10.1182/blood.2019004701	journal	November 2020
Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients Reiners, Katrin S.; Kessler, Jörg; Sauer, Maike Molecular Therapy, Vol. 21, Issue 4 https://doi.org/10.1038/mt.2013.14	journal	April 2013
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Rothe, Achim; Sasse, Stephanie; Topp, Max S. Blood, Vol. 125, Issue 26 https://doi.org/10.1182/blood-2014-12-614636	journal	June 2015
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30⁺tumor cells Reusch, Uwe; Burkhardt, Carmen; Fucek, Ivica mAbs, Vol. 6, Issue 3 https://doi.org/10.4161/mabs.28591	journal	March 2014
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene Cartron, Guillaume; Dacheux, Laurent; Salles, Gilles Blood, Vol. 99, Issue 3 https://doi.org/10.1182/blood.V99.3.754	journal	February 2002
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ neu –Positive Metastatic Breast Cancer Musolino, Antonino; Naldi, Nadia; Bortesi, Beatrice Journal of Clinical Oncology, Vol. 26, Issue 11 https://doi.org/10.1200/JCO.2007.14.8957	journal	April 2008
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma Casneuf, Tineke; Xu, Xu Steven; Adams, Homer C. Blood Advances, Vol. 1, Issue 23 https://doi.org/10.1182/bloodadvances.2017006866	journal	October 2017
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity Ellwanger, Kristina; Reusch, Uwe; Fucek, Ivica mAbs, Vol. 11, Issue 5 https://doi.org/10.1080/19420862.2019.1616506	journal	June 2019
Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry Alaterre, Elina; Raimbault, Sébastien; Garcia, Jean-Michel Cytometry Part B: Clinical Cytometry, Vol. 94, Issue 3 https://doi.org/10.1002/cyto.b.21590	journal	September 2017
Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen Density Niwa, R. Clinical Cancer Research, Vol. 11, Issue 6 https://doi.org/10.1158/1078-0432.CCR-04-2263	journal	March 2005
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. Carson, W. E.; Giri, J. G.; Lindemann, M. J. Journal of Experimental Medicine, Vol. 180, Issue 4 https://doi.org/10.1084/jem.180.4.1395	journal	October 1994
FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype Koene, Harry R.; Kleijer, Marion; Algra, Johan Blood, Vol. 90, Issue 3 https://doi.org/10.1182/blood.V90.3.1109	journal	August 1997
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. Wu, J.; Edberg, J. C.; Redecha, P. B. Journal of Clinical Investigation, Vol. 100, Issue 5 https://doi.org/10.1172/JCI119616	journal	September 1997
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma Kyle, Robert A.; Gertz, Morie A.; Witzig, Thomas E. Mayo Clinic Proceedings, Vol. 78, Issue 1 https://doi.org/10.4065/78.1.21	journal	January 2003
Engineering an APRIL-specific B Cell Maturation Antigen Patel, Darshana R.; Wallweber, Heidi J. A.; Yin, JianPing Journal of Biological Chemistry, Vol. 279, Issue 16 https://doi.org/10.1074/jbc.M312316200	journal	April 2004
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells Chen, Haiming; Li, Mingjie; Xu, Ning Leukemia Research, Vol. 81 https://doi.org/10.1016/j.leukres.2019.04.008	journal	June 2019
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients Ghermezi, Michael; Li, Mingjie; Vardanyan, Suzie Haematologica, Vol. 102, Issue 4 https://doi.org/10.3324/haematol.2016.150896	journal	December 2016
Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial Trudel, Suzanne; Lendvai, Nikoletta; Popat, Rakesh The Lancet Oncology, Vol. 19, Issue 12 https://doi.org/10.1016/S1470-2045(18)30576-X	journal	December 2018
Abstract LB-299: Cynomolgus monkey plasma cell gene signature to quantify the in vivo activity of a half-life extended anti-BCMA BiTE® for the treatment of multiple myeloma Goyos, Ana; Li, Chi-Ming; Deegen, Petra Cancer Research, Vol. 78, Issue 13_Supplement https://doi.org/10.1158/1538-7445.AM2018-LB-299	journal	July 2018
Putting J Chain Back on the Map: How Might Its Expression Define Plasma Cell Development? Castro, Caitlin D.; Flajnik, Martin F. The Journal of Immunology, Vol. 193, Issue 7 https://doi.org/10.4049/jimmunol.1400531	journal	October 2014
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma van de Donk, Niels W. C. J.; Casneuf, Tineke; Di Cara, Alessandro British Journal of Haematology, Vol. 184, Issue 3 https://doi.org/10.1111/bjh.15122	journal	February 2018
The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas Velders, Mp; van Rhijn, Cm; Oskam, E. British Journal of Cancer, Vol. 78, Issue 4 https://doi.org/10.1038/bjc.1998.518	journal	August 1998
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells Wang, Yufeng; Zhang, Yibo; Hughes, Tiffany Clinical Cancer Research, Vol. 24, Issue 16 https://doi.org/10.1158/1078-0432.CCR-17-3117	journal	August 2018
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma Lamb, Yvette N. Drugs, Vol. 78, Issue 14 https://doi.org/10.1007/s40265-018-0969-4	journal	September 2018
Daratumumab for the Treatment of Multiple Myeloma Plesner, Torben; Krejcik, Jakub Frontiers in Immunology, Vol. 9 https://doi.org/10.3389/fimmu.2018.01228	journal	June 2018
Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities Liu, Pan; Jin, Yanxia; Sattar, Haseeb Journal of Leukocyte Biology, Vol. 103, Issue 5 https://doi.org/10.1002/JLB.2RU0517-176RR	journal	May 2018
Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells Luna, Jesus; Grossenbacher, Steven; Sturgill, Ian Cancers, Vol. 11, Issue 1 https://doi.org/10.3390/cancers11010085	journal	January 2019

Similar Records

Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer

Journal Article · 2022 · Molecular Cancer Therapeutics · OSTI ID:1870743

Wang, Peiyin; Sun, Liping L.; Clark, Robyn; +22 more

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

Journal Article · 2024 · MAbs · OSTI ID:2470046

McCue, Amelia C.; Demarest, Stephen J.; Froning, Karen J.; +3 more

Related Subjects

Oncology
Hematology

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

Citation Formats

References (36)

Similar Records

Related Subjects